Sounds pretty good to me.

First 3 Last

Share
Profile

Follow
moosey

20,260 Posts.

1790

13/07/21

09:31

Post #: 54458699
Share

Originally posted by moosey ↑

PolyNovo LimitedABN 96 083 866 8622/320 Lorimer StreetPort Melbourne VIC Australia 3207P +61 (0) 3 8681 4050F +61 (0) 3 8681 409913 July 2021ASX Announcement Building Momentum - Record US Turnover in June’21 and 4Q21, US Sales Team Increased to 36
Notwithstanding limited access to US hospitals and surgeons due to Covid, PolyNovo is experiencing increasing revenue momentum in the US and all other major markets. PolyNovo US reports more than 50 per cent of hospitals are now re-engaging for business. At the same time, the US sales team has been expanded to 36 with 6 new staff trained in the last month. This will expand our geographic footprint and our ability to service recently signed Group Purchasing Organisations. While FY21 BTM revenue growth of circa 34% is a good indicator of FY21 BTM financial performance, recent business fundamentals have significantly improved as follows:•US BTM revenue in $US has grown 49% in FY21 over FY20.•US 4Q21 BTM revenue is a record $US 4.9M compared with 4Q20 of $US 3.3M•Record monthly BTM revenue of $A 3.3M in June ’21 •FY21 Distributor revenue growth was 53% with strong increases in the DACH region (Germany, Switzerland, and Austria), further sales in South Africa and India, good first sales in Finland, Italy, and Taiwan.•FY21 Australia BTM revenue has grown 25 per cent despite challenging Covid lockdownsManaging Director, Paul Brennan said, “FY21 has tested our teams with rolling Covid impacts but they responded with dedication and creativity to service customers. We continue to see expansion of sales outside of burns and we have increasing momentum as we head into FY22. I look forward to providing a comprehensive update when we announce our year end result.” Chairman David Williams said,“I expect FY22 to be very strong financial performance even without a full world-wide recovery from Covid given the current momentum within the business.”Full audited results will be released on 26 August 2021. This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

Expand

Sounds pretty good to me.

PNV Price at posting: $2.38 Sentiment: Buy Disclosure: Held
21 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

OJC

SPC to merge with Original Juice Co and Nature One Dairy

There are more pages in this discussion • 168 more messages in this thread...

First 3 Last

Add PNV (ASX) to my watchlist

(20min delay)
Last $2.59		Change -0.060(2.26%)		Mkt cap ! $1.788B

Open	High	Low	Value	Volume
$2.60	$2.68	$2.58	$5.065M	1.931M

Buyers (Bids)

No.	Vol.	Price($)
4	42339	$2.59

Sellers (Offers)

Price($)	Vol.	No.
$2.61	10000	1

View Market Depth

No.	Vol.	Price($)
4	42339	2.590
6	39914	2.580
2	18122	2.570
3	159755	2.560
6	16407	2.550

Price($)	Vol.	No.
2.610	10000	1
2.620	11370	3
2.630	40475	7
2.640	11370	2
2.650	51156	5

Last trade - 16.10pm 02/10/2024 (20 minute delay)

PNV (ASX) Chart

Sounds pretty good to me.

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SPC to merge with Original Juice Co and Nature One Dairy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Sounds pretty good to me.

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SPC to merge with Original Juice Co and Nature One Dairy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News